PARIS, FRANCE, February 6, 2023-- AGS Therapeutics is a biotech company developing innovative biomedicines based on extracellular vesicles from microalgae (MEV), a new kind of safe, targeted, and highly versatile delivery system for therapeutic molecules from natural and synthetic biology designed to address a wide range of illnesses will make a virtual company presentation at the BIO CEO & Investor Conference at the Marriot Marquis in New York City.

‍

Dr. Manuel Vega, CEO and Co-founder will update investors on the AGS technology for a novel drug delivery system. 

‍

Widespread use of today’s innovative biologics - RNA, DNA, proteins, gene editing complexes, and gene expression plasmids - for the treatment of human diseases remains elusive due, in part, to our collective inability to deliver therapeutic doses to the right target in the body without affecting other organs or tissues. The lack of an effective drug delivery system (DDS), which can overcome the human body’s natural barriers, has been a significant bottleneck in unleashing the power of the most advanced biologics as effective biomedicines for patients.

‍

About AGS Therapeutics

AGS Therapeutics, based in Paris, France, is a biotech company developing biomedicines based on extracellular vesicles from microalgae (MEV) as a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, DNA, and proteins for a broad range of human diseases. AGS-M, the company’s subsidiary and a contract development and manufacturing organization, will produce the MEV needed to support preclinical and clinical development of MEV-based product pipelines from AGS and from pharmaceutical companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

‍

Contact:

Dan Eramian

Opus Biotech Communications

425-306-8716